Mirtazapine Augmentation in Resistant Obsessive Compulsive Disorder
Phase 3
- Conditions
- Obsessive -compulsive disorder.Obsessive-compulsive disorder
- Registration Number
- IRCT20201004048919N1
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
people who have been diagnosed with obsessive -compulsive disorder based on DSM5.
People with a yale-brown obsessive compulsive scale above 15.
Has an age range of 18 to 60 years.
Exclusion Criteria
Pregnant women and breastfeeding
People receivinig psychotherapy.
having major physical illnesse: liver problems (they have high liver enzymes),kidney problems(BUN ,CR are high), thyroid problem, trouble breathing.
They have other psychiatric problems: According to the DSM5 criteria, they have psychotic disorder, anxiety disorder, dementia, mood disorder, and mental retardation.
use drugs or alcohol
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The severity of the symptoms of obsessive -compulsive disorder. Timepoint: The beginning of the study and 2-4-6-8-12 weeks after the start of treatment. Method of measurement: Based on the questionnaire Y-BOCS.
- Secondary Outcome Measures
Name Time Method